To discover more feel free to contact us:
The immediate addressable market for the BVT bionic eye includes subjects with Retinitis Pigmentosa (RP) who have no remaining vision, or have residual vision which is far worse than 20/200 (legal blindness). RP is a genetically linked disease and is the major cause of inherited blindness, affecting 1:4000 people in the Western world and as many as 1:400 in Southern India and parts of China.1 The disease is characterised by the progressive loss of photoreceptor cells and peripheral vision and is associated with night-vision difficulties.
1)Novel surgical technique providing greater safety
and stability of devices
2)World leading, pioneering vision processing software
The intellectual property portfolio consists of seven granted patents, 45 patent applications and four provisional patents. Bionic Vision Technologies Pty Ltd, holds licences to all the patents.